✦ LIBER ✦

47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I study

✍ Scribed by M.R. Weihrauch; H. Richly; M.S. von Bergwelt-Baildon; U. Hacker; A. Shimabukuro-Vornhagen; B. Nokay; M. Tschaika; M. Schmidt; B. Wittig; M.E. Scheulen

Book ID: 119602730
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 43 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)71752-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

46 Immunotherapy with the toll-like rece

46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study

✍ M.R. Weihrauch; M.S. von Bergwelt-Baildon; U. Hacker; H. Richly; U. Holtick; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

44LBA Results of a phase I clinical tria

44LBA Results of a phase I clinical trial of MGN1703, a novel TLR9-agonist, in patients with metastatic malignancies

✍ M. Weihrauch; M. Schmidt; M. Tschaika; H. Richly; M.S. von Bergwelt-Baildon; U. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Phase II Trial of a Toll-Like Receptor 9

Phase II Trial of a Toll-Like Receptor 9-Activating Oligonucleotide in Patients With Metastatic Melanoma

✍ Pashenkov, M.; Goess, G.; Wagner, C.; Hormann, M.; Jandl, T.; Moser, A.; Britten 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 777 KB

P-359 Results from a phase I study of th

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

✍ Wheeler, Catherine; Minami, Hironobu; Ebi, Hiromichi; Tahara, Makoto; Sasaki, Ya 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB

9148 Phase 1 study of the toll-like rece

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Smith, D.A.; Conkling, P.; Richards, D.; Alemany, C.; Boyd, T.; Garbo, L.; Wu, H 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Phase I Active Immunotherapy With Combin

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

✍ Kaumaya, P. T.P.; Foy, K. C.; Garrett, J.; Rawale, S. V.; Vicari, D.; Thurmond, 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 217 KB